Lucida Medical

We will be at ECR 2026, 4-8 March 2026! 📍 Booth location: AI‑32, AI Exhibition Area 🔗 Book a meeting with our team: @lucidamedical.com/?ismsaljsauthenabled" target="_blank" rel="nofollow noopener">outlook.office.com/book/ECR2026@l… We look forward to meeting colleagues and partners in Vienna to discuss how evidence‑based AI can strengthen prostate cancer care.

AI decision support in prostate MRI can boost accuracy, cut variability, and sharpen decisions on PI‑RADS 3 cases. The challenge is using AI insight without slipping into automation bias. How do you see this shaping everyday reporting?

We welcome Dr. Luca Russo as Clinical Lead on our Medical Advisory Board! He is a Radiologist at Gemelli Hospital, a Clinical Research Fellow at The Royal Marsden in London, and holds a PhD in Oncological Sciences. His expertise will further strengthen our clinical impact!

2025 has been a year of progress at Lucida Medical: new clinical validations, product upgrades, partnerships, and impactful congresses. With trust, passion and vision, we look forward to 2026, driving innovation and reaching new milestones in the prostate care pathway.

When AI acts as a second reader, MDTs gain safety checks but face new risks: bias, trust gaps, overdiagnosis. How can teams strike balance between AI’s sensitivity & human judgment in biopsy decisions? Full paper: link.springer.com/article/10.100…

For this year’s Christmas party, we gathered at King’s College in Cambridge 🎄 The setting was iconic, but what mattered most was the chance to pause and see each other. We close the year proud of the progress made, and we are excited for the milestones ahead!

Improving early detection and tackling inequalities in prostate cancer screening is vital, and we’re proud to support our partners at Prostate Cancer Research in raising awareness of this important issue. Find out more and add your voice here: act.prostate-cancer-research.org.uk/a/say-yes-to-s…

We are thrilled to complete the first prostate fusion biopsy procedure at our pilot site Hampshire Hospitals NHS Foundation Trust! The procedure was performed through @SectraNews Amplifier Service, and combined with the @KoelisBx Trinity®. Read more: lucidamedical.com/press-release-…

#RSNA2025 is almost here and we’re excited to share new research on how AI decision support could enable significant biopsy reduction. This multicentre study integrates PI-RADS, PSA density, and AI risk scores to sharpen biopsy selectivity. Join us on Dec 2 to learn more!

Lucida Medical’s first newsletter arrives this week! Be among the first to receive updates on milestones, research, and product developments. 📩 Sign up before launch: lucidamedical.com/newsletter-sub…

At Gemelli Hospital in Rome, radiologists have introduced Lucida Medical’s Prostate Intelligence (Pi™) into daily practice. The result? Faster reporting, more confident diagnoses, and better collaboration with urology teams. Read the full customer story: lucidamedical.com/customer-story…

Lucida Medical is heading to RSNA 2025 taking place from 30 November - 4 December at McCormick Place, Chicago. We will be at Booth 5532. 📍 Find our location on the map: rsna2025.mapyourshow.com/8_0/floorplan/… 🔗 Book a meeting with our team: @lucidamedical.com/?ismsaljsauthenabled" target="_blank" rel="nofollow noopener">outlook.office.com/book/RSNA2025@… #rsna2025 @RSNA

We’re pleased to announce Professor Anwar Padhani (@ProfPadhani) as Lucida Medical’s Chief Medical Officer! A global expert in oncological MRI and prostate cancer imaging, he will lead our clinical strategy to ensure our AI solutions meet real-world cancer care needs. Welcome!

Part 2: AI-targeted review AI flags all suspicious lesions on MRI. Radiologists verify each region and double-check negatives. This boosts detection, streamlines reporting, and reduces variability. Full paper: lnkd.in/diWn-bMU @ProfPadhani

Lucida Medical is proud to join the new Harrison.ai Open Platform - zero markup, open access, and seamless integration. Together, we’re making AI for prostate cancer detection more accessible, accurate, and cost-effective. Learn more: businesswire.com/news/home/2025…

A new AI-powered ‘one-day diagnostics’ service could transform the diagnosis of prostate cancer. The pilot, due to start early next year, aims to give men a same-day all clear or a cancer diagnosis within a few days, saving weeks of worry. ➡️ england.nhs.uk/2025/10/nhs-ar…

NHS England is to test a 'one-day diagnostics' service for prostate cancer, using the Pi AI tool and saying it could save some men up to a month of waiting. ukauthority.com/articles/nhs-e… @LucidaMedical #NHS #cancer #AI #medtech

Read more: bbc.com/news/articles/… telegraph.co.uk/news/2025/10/2… news.sky.com/story/nhs-to-o…

Same-day prostate cancer diagnosis is set to be trialled at Leeds Teaching Hospitals NHS Trust using Lucida Medical’s AI solution. We are proud to support faster, more efficient care for patients. Featured today in BBC News, The Telegraph, The Times & more UK media outlets

Part 1: High-confidence filtering AI reviews MRI scans and escalates only borderline cases to radiologists. This workflow improves efficiency, supports biopsy decisions, and reduces unnecessary re-reviews. Full paper: link.springer.com/article/10.100…